Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Top Cited Papers
Open Access
- 22 August 2013
- journal article
- Published by American Society of Hematology in Blood
- Vol. 122 (8), 1395-1398
- https://doi.org/10.1182/blood-2013-03-488098
Abstract
Key Points. Treatment response criteria for MF must capture drug benefit in terms of symptom burden.The current document includes stricter definitions of red cKeywords
This publication has 22 references indexed in Scilit:
- Primary myelofibrosis: 2013 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2013
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment StrategiesJournal of Clinical Oncology, 2011
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in MyelofibrosisNew England Journal of Medicine, 2010
- Pomalidomide Is Active in the Treatment of Anemia Associated With MyelofibrosisJournal of Clinical Oncology, 2009
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conferenceBlood, 2009
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and TreatmentBlood, 2009
- Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatmentLeukemia, 2007
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006
- Report of an international working group to standardize response criteria for myelodysplastic syndromes.2000